UPDATE 1-CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

1

(Adds more details and background from paragraph 2 onwards) Oct 5 (Reuters) – Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)